News | September 06, 2021
CRAMS to drive growth for Indian pharma industry: report
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
The transactions resulted in a net cash inflow of Rs 183 crores for HCG in addition to the take-over of the labs and clinical research business
The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
The lab will offer about 4,000 different tests ranging from basic to high-end molecular diagnostic tests
Acetaminophen extended-release tablets 650 mg is bioequivalent of the reference listed drug Tylenol
The segment delivered strong sales growth of 20% YoY
This is Enzene Biosciences third biosimilar to be approved
The centre established by Nucleome Informatics will take up the sequencing of 5,000 Covid genomes and 500 human genomes in the coming months
The product will be available in 500 mg/2.5 mL and 1 g/5 mL vials
Subscribe To Our Newsletter & Stay Updated
